| DC47053 |
Tigulixostat
Featured
|
Tigulixostat is a novel (indolyl)heteroarylcarboxylate derivatives effective as non-purine selective xanthine oxidase inhibitor, which lowers the production of uric acid. |
|
| DC47087 |
Orismilast |
Orismilast (LEO-32731) is a PDE4 inhibitor used for the research of inflammatory diseases. |
|
| DC47095 |
Larsucosterol sodium |
Larsucosterol sodium is a cholesterol metabolite from the nuclei of normal human liver tissues, epigenetically regulates the transcription of proteins and enzymes involved in lipid synthesis, inflammation, and apoptosis. |
|
| DC47102 |
SSAO inhibitor-1 |
SSAO inhibitor-1 is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor. SSAO inhibitor-1 has anti-inflammatory activity and can be used for liver diseases research. |
|
| DC47116 |
Deutarserine |
Deutarserine is a deuterium modified analog of endogenous D-serine (CTP 692), which is used in the research of adults with schizophrenia. |
|
| DC47141 |
Triiodothyronine sulfate |
Triiodothyronine sulfate is the main metabolite of thyroid hormone triiodothyronine (T3). Triiodothyronine is an active form of thyroid hormone, which binds to β1 thyroid hormone receptor (TRβ1), and activates its activity. |
|
| DC47165 |
CDC25B-IN-2
Featured
|
CDC25B-IN-2 is a potent cdc25B inhibitor. |
|
| DC47166 |
CRA-2059 TFA |
CRA-2059 is a highly specific and selective tryptase inhibitor, with a Ki of 620 pM for recombinant human tryptase-β (rHTβ). |
|
| DC47182 |
Tilpisertib |
Tilpisertib is a serine/threonine kinase inhibitor (WO2017007689). |
|
| DC47198 |
IHVR-11029 |
IHVR-11029 is a small molecule inhibitor of ER α-glucosidases, with an EC50 of 0.09 μM. |
|
| DC47199 |
Salsolidine hydrochloride |
Salsolidine hydrochloride, a tetrahydroisoquinoline alkaloid, acts as a stereoselective competitive MAO A (monoamine oxidase A) inhibitor. |
|
| DC47200 |
BN82002 hydrochloride |
BN82002 hydrochloride is a potent, selective and irreversible inhibitor of CDC25 phosphatase family. BN82002 hydrochloride inhibits CDC25A, CDC25B2, CDC25B3, CDC25C CDC25A, and 25C-cat with IC50 values of 2.4, 3.9, 6.3, 5.4, and 4.6 µM, respectively. BN82002 hydrochloride displays ~20-fold greater selectivity over CD45 tyrosine phosphatase. |
|
| DC47201 |
Irsenontrine |
Irsenontrine (E2027) is an orally active and selective phosphodiesterase 9 (PDE 9) inhibitor. Irsenontrine can be used for the research of neurological diseases. |
|
| DC47214 |
Phosphoribosyl pyrophosphate pentasodium |
Phosphoribosyl pyrophosphate (PRPP) pentasodium is an important metabolite required in the biosynthesis of purine and pyrimidine nucleotides, the amino acids histidine and tryptophan, and the cofactors NAD and NADP. |
|
| DC47223 |
Ro 20-1724 |
Ro 20-1724 (Ro 20-174) is a potent inhibitor of cAMP-specific phosphodiesterase (PDE4/PDE IV) with a Ki of 1930 nM. Neuroprotective effect. |
|
| DC47233 |
Kynuramine dihydrochloride |
Kynuramine, an endogenously occurring amine, is a fluorescent substrate and probe of plasma amine oxidase. |
|
| DC47239 |
Zanapezil free base |
Zanapezil (TAK-147) free base is a potent, reversible and selective acetylcholine esterase (AChE) inhibitor. Zanapezil free base shows a potent and reversible inhibition of AChE activity in homogenates of the rat cerebral cortex (IC50=51.2 nM). Zanapezil free base shows a moderate inhibition of muscarinic M1 and M2 receptor binding with Ki values of 234 and 340 nM, respectively. Zanapezil free base can be used for the research of early stages of Alzheimer's disease (AD). |
|
| DC47297 |
SLN124 |
SLN124 is a GalNac-siRNA targeting transmembrane serine protease 6 (Tmprss6). SLN124 is composed of a trimeric GalNAc ligand conjugated to TMPRSS6‐siRNA. SLN124 has the potential for an siRNA to restore hepcidin expression and normalise iron homeostasis in β‐thalassaemia. |
|
| DC47299 |
Fitusiran |
Fitusiran (ALN-AT3SC), an small interfering RNA, specifically targets antithrombin (AT) messenger RNA to lower production of AT in the liver. Fitusiran increases thrombin generation and has the potential for the research of the hemophilia. |
|
| DC47337 |
PCSK9-IN-2 |
PCSK9-IN-2 is a novel small molecule inhibitor of PCSK9-LDLR protein–protein interaction (PPI) with an IC50 value of 7.57 μM. |
|
| DC47357 |
D-Cl-amidine hydrochloride |
D-Cl-amidine hydrochloride is a potent and highly selective PAD1 inhibitor. D-Cl-amidine is well-torelated with no significant toxicity. |
|
| DC47386 |
N-Desmethyl Sildenafil |
N-Desmethyl Sildenafil (Desmethylsildenafil) is a major metabolite of Sildenafil. Sildenafil is a potent phosphodiesterase type 5 (PDE5) inhibitor. |
|
| DC47387 |
PDE4-IN-3 |
PDE4-IN-3 is a novel and orally active PDE4 inhibitor with potent inhibitory affinity (IC50 = 4.2 nM). |
|
| DC47388 |
PROTAC SHP2 degrader-1
Featured
|
PROTAC SHP2 degrader-1 is a potent and effective SHP2 degrader. PROTAC SHP2 degrader-1 induces SHP2 degradation requires binding to VHL-1 and SHP2 proteins and is also neddylation- and proteasome-dependent. |
|
| DC47389 |
PTP1B-IN-13 |
PTP1B-IN-13 is a selective PTP1B inhibitor targeting the allosteric site with an IC50 value of 1.59 μM. |
|
| DC47390 |
PTP1B-IN-14 |
PTP1B-IN-14 is a selective PTP1B inhibitor (IC50 = 0.72 μM) targeting the allosteric site. |
|
| DC47391 |
Okadaic acid ammonium salt |
Okadaic acid, a marine toxin, is an inhibitor of protein phosphatases (PP), including PP1 (IC50=15-50 nM), PP2A (IC50=0.1-0.3 nM), PP3 (IC50=3.7-4 nM), PP4 (IC50=0.1 nM), PP5 (IC50=3.5 nM), with a significantly higher affinity for PP2A. Okadaic acid increase of phosphorylation of a number of proteins by inhibiting PP, and acts a tumor promoter. |
|
| DC47408 |
28-O-β-D-Glucopyranosyl pomolic acid |
28-O-β-D-Glucopyranosyl pomolic acid is a urokinase plasminogen activator inhibitor with IC50 at 37.82 μM. |
|
| DC47409 |
ACT001 |
ACT001 is orally active PAI-1 inhibitor by inhibiting the phosphorylation of PI3K and AKT. ACT001 inhibits the phosphorylation of STAT3 and PD-L1 expression by directly binding to STAT3. ACT001, a fumarate salt form of Micheliolide, can cross the blood-brain barrier. ACT001 has potent anti-glioblastoma (GBM) activity and immunomodulatory effects.
|
|
| DC47410 |
Liarozole dihydrochloride |
Liarozole Dihydrochloride is identified as a modest inhibitor of P450 with IC50 of 2.2–6.0 μM and 260 nM for CYP26 and rat CYP17 respectively. |
|
